A Phase 3 interventional study of bevacizumab and ranibizumab in Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration and Wet Macular Degeneration, sponsored by Outlook Therapeutics, Inc.. Completed at 9 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Outlook Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
This study's enrollment of 61 is below the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Browse Wet Macular Degeneration studies →Outlook Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study eye must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONS-5010
Biological: bevacizumab
Biological: ranibizumab
1.25 mg, intravitreal injection
Also known as: ONS-5010
0.5mg, intravitreal injection
Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score
BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.
Time frame: Baseline, 11 months
Mean change in the best corrected visual acuity over time
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
Time frame: Baseline, monthly to 11 months
Proportion of participants who gain at least 10 letters in the best corrected visual acuity score
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
Time frame: Baseline, 11 months
Proportion of participants who gain at least 5 letters in the best corrected visual acuity score
BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.
Time frame: Baseline, 11 months
Proportion of participants who lose fewer than 15 letters in the best corrected visual acuity score
BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity.
Time frame: Baseline, 11 months
Proportion of participants with visual-acuity Snellen equivalent of 20/200 or worse
Time frame: Baseline, 11 months
Percentage of participants with ocular adverse events, non-ocular adverse events, grade 3 and above laboratory abnormalities, and vital sign abnormalities
Time frame: 11 months, 12 months
Plan to share: Undecided — Data will not be shared until all global regulatory filings are complete.
No publications or documents are linked to this record.
Ran from Oct 2018 to primary completion in Jul 2020, 21 months.
Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 21 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab
Outlook Therapeutics, Inc.